AgomAb Therapeutics NV (AGMB) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($461.5 million vs $449.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | RZLT |
|---|---|---|
| Share price | $9.37 | $4.65 |
| Market cap | $461.45M | $449.28M |
| 1-day change | +1.63% | +0.11% |
| YTD return | — | +96.61% |
| 1-year return | — | -46.79% |
| 5-year return | — | -30.23% |
| EPS (TTM) | $-2.08 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $11.46 |
| 52-week low | $7.97 | $1.07 |
| Distance from 52-week high | -47.42% | -59.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +302.03% | +110.98% |
| Average volume | 139.21K | 1.50M |
| Shares outstanding | 49.25M | 96.72M |
| Employees | 62 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
AGMB vs RZLT FAQ
Which is bigger, AgomAb Therapeutics NV or Rezolute?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $461.45M compared with $449.28M for Rezolute (RZLT).
Are AgomAb Therapeutics NV and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Rezolute.